3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
7
Ureteral Neoplasms
3
Urologic Neoplasms
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Adenocarcinoma of the Bladder
1
Interventions
durvalumab
3
Fulvestrant
3
Cisplatin
3
pembrolizumab
2
abemaciclib
2
Pemetrexed
2
Carboplatin
2
ribociclib
1
repotrectinib
1
palbociclib
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
STX-478
1
Radiation Dose Hypofractionation
1
RAD1901
1
Oviposition
1
Nivolumab
1
Mitomycin
1
Metformin
1
Letrozole
1
Immunotherapy
1
Imlunestrant
1
Gemcitabine
1
Fluorouracil
1
Drug Therapy
1
Drainage
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
enfortumab vedotin
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled